Last reviewed: June 22, 2026
Last updated: June 22, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
The question of who qualifies for semaglutide-based weight management has shifted from a simple BMI cutoff to a more personalized clinical picture. Unlike brand-name Ozempic®, which carries specific FDA-labeled indications, PlexusDx compounded semaglutide serves patients across varied metabolic profiles through a precision-medicine lens that considers individual health markers alongside body composition.
Understanding Semaglutide Qualification Beyond BMI Numbers
Traditional weight loss drug eligibility once hinged on meeting a BMI threshold of 30 or higher, or 27 with weight-related conditions. However, clinical evidence now supports a broader view: qualification depends on metabolic readiness, weight-loss history, and the presence of obesity-related diseases such as type 2 diabetes or cardiovascular risk factors. PlexusDx evaluates each patient's complete health timeline rather than relying on a single number on the scale.
Body mass index remains an important screening tool, but it captures only part of the story. Two patients with identical BMI values may have vastly different insulin resistance levels, appetite-regulation pathways, or genetic predispositions to weight gain. The GLP-1 receptor, which semaglutide activates, influences satiety, gastric emptying, and glucose control—mechanisms that respond differently based on individual biology. PlexusDx uses this understanding to match patients with the right therapeutic approach.
Clinical Criteria That Determine GLP-1 Candidacy
Patients typically qualify for semaglutide if they meet one of these criteria: a BMI of 30 kg/m² or higher; a BMI of 27 kg/m² or higher with at least one weight-related condition (type 2 diabetes, hypertension, sleep apnea, heart disease); or a documented history of failed weight-loss attempts with diet and exercise alone. Additionally, patients who have regained weight after previous loss or who carry visceral fat despite appearing relatively lean may benefit from GLP-1 therapy based on metabolic markers rather than appearance.
Beyond basic eligibility, PlexusDx screens for contraindications such as personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, or active pancreatitis. Age, kidney function, and current medication use all factor into the safety assessment. Patients with stable type 2 diabetes, prediabetes, or obesity-associated insulin resistance often show the strongest response, as semaglutide addresses the root metabolic dysfunction driving weight gain rather than simply suppressing appetite.
How PlexusDx Personalizes Semaglutide Therapy
PlexusDx begins with a straightforward health questionnaire and consultation to establish candidacy, then offers the Precision Peptide Genetic Test as an optional add-on after the first month of treatment. This genetic analysis examines key variants in GLP-1 receptor pathways (GLP1R rs6923761), glucose-dependent insulinotropic polypeptide signaling (GIPR rs1800437), metabolic rate genes (FTO rs9939609), and appetite-control circuits (MC4R rs17782313). These insights map across 14 biological pathways and 150+ genetic markers to predict individual response patterns.
The result is a tailored semaglutide protocol suited to your unique metabolism. Some patients respond optimally to standard compounded semaglutide injection, available from PlexusDx starting at $149 per month. Others may benefit from oral semaglutide ($249/mo), dual-compound GLP-Squared ($249/mo injection or $369/mo oral), or the microdose protocol ($129/mo) if sensitivity or comorbidities call for a gentler dose escalation. Your dose may need to go up. Your price won't.
Cost and Access: No Insurance, No Membership Required
PlexusDx serves all 50 states and accepts no insurance requirement, eliminating prior-authorization delays and coverage denials that often block access to compounded GLP-1 therapy. All medications compound at licensed 503A pharmacies—facilities that meet strict USP <797> standards for sterile preparation and quality assurance. This is not 503B pharmaceutical manufacturing; PlexusDx compounds to order, ensuring freshness and potency.
Pricing is transparent and commitment-based across three tiers, with semaglutide injection starting at $149 monthly on the most flexible plan. HSA and FSA accounts are eligible, reducing out-of-pocket burden for those with tax-advantaged savings. The Precision Peptide Genetic Test adds $99 after your first month, unlocking deeper insights into why your body may resist weight loss and which mechanism—appetite, insulin sensitivity, or metabolic rate—PlexusDx should prioritize in your treatment plan.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What if my BMI is under 30 but I have type 2 diabetes or sleep apnea—do I still qualify?
Yes. Clinical guidelines recognize that patients with a BMI of 27 or higher and weight-related comorbidities like type 2 diabetes, hypertension, or obstructive sleep apnea qualify for GLP-1 therapy. PlexusDx evaluates the full picture of your health, not just your BMI, to determine candidacy.
How does PlexusDx compounded semaglutide differ from brand-name Ozempic® or Wegovy®?
PlexusDx sources compounded semaglutide from licensed 503A pharmacies, delivering the same active pharmaceutical ingredient at lower cost ($149/mo vs. brand prices). Compounded medications are not FDA-approved but are made to pharmaceutical standards under strict USP <797> sterile compounding guidelines. Many patients find compounded options more accessible and affordable.
Can genetics predict whether I'll respond well to semaglutide?
The Precision Peptide Genetic Test maps variants in your GLP-1 receptor, appetite-control genes (MC4R, FTO), and glucose-sensing pathways to predict response strength. While not pharmacogenomic testing, it reveals which metabolic pathway drives your weight gain and helps PlexusDx select the most effective compound and dose protocol for you.
What happens if I'm interested but not currently a PlexusDx patient—how do I get started?
PlexusDx conducts a brief health consultation to confirm eligibility, then ships compounded semaglutide to your door. No membership, no insurance needed, and no membership fees. Patients in all 50 states can access therapy starting at $149/month, with optional genetic testing available after your first month.
Are there any reasons PlexusDx would advise against semaglutide for me?
Yes. PlexusDx screens for personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, active pancreatitis, and severe kidney disease. Patients on certain medications or with unstable medical conditions may need dose adjustment or alternative approaches. A consultation clarifies any concerns.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Finding Success Again: Why Has Wegovy Stopped Working for Me and How to Break the Plateau
How Do I Know Wegovy Is Working? A Guide to Tracking Your Progress